​

Zentalis Pharmaceuticals Ownership | Who Owns Zentalis Pharmaceuticals?

OverviewForecastFinancialsChart

Zentalis Pharmaceuticals Ownership Summary

Zentalis Pharmaceuticals is owned by 30.44% institutional investors, 22.46% insiders, and 47.10% retail investors. Blackrock is the largest institutional shareholder, holding 6.80% of ZNTL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.96% of its assets in Zentalis Pharmaceuticals shares.

ZNTL Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockZentalis Pharmaceuticals30.44%22.46%47.10%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock4.82M6.80%$19.71M
Renaissance2.88M4.00%$3.89M
Vanguard group2.86M3.96%$3.86M
Acadian asset management2.85M3.95%$3.84M
Tang capital management1.55M2.15%$2.34M
Two sigma advisers, lp1.46M2.03%$2.21M
Two sigma investments, lp1.36M1.89%$2.06M
Decheng capital1.32M1.83%$1.79M
D. e. shaw1.24M1.74%$3.76M
Blackrock funding, inc. /de1.25M1.73%$1.69M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mayo clinic187.14K25.27%$765.41K
Tybourne capital management (hk)961.49K4.69%$1.45M
Stonepine capital management453.80K0.56%$685.24K
Pfizer953.83K0.54%$1.29M
Peapod lane capital448.86K0.52%$605.96K
5am venture management490.00K0.27%$739.90K
Decheng capital1.32M0.24%$1.79M
Almitas capital457.32K0.16%$690.56K
Gsa capital partners llp1.17M0.14%$1.58M
Anfield capital management242.60K0.10%$327.52K

Top Buyers

HolderShares% AssetsChange
Balyasny asset management970.86K0.00%970.86K
Renaissance2.88M0.01%558.39K
Barclays568.44K0.00%406.97K
Connor, clark & lunn investment management787.05K0.00%406.23K
Stonepine capital management453.80K0.56%344.79K

Top Sellers

HolderShares% AssetsChange
Matrix capital management company, lp---13.96M
Eventide asset management---4.48M
Opaleye management316.55K0.07%-1.61M
T. rowe price investment management---1.33M
Almitas capital457.32K0.16%-1.14M

New Positions

HolderShares% AssetsChangeValue
Norges bank71.53K-71.53K$292.55K
Voleon capital management lp27.16K0.00%27.16K$41.01K
Sivia capital partners20.00K0.01%20.00K$27.00K
Optiver b.v.44.00-44.00$66.00
Allworth financial lp42.00-42.00$49.00

Sold Out

HolderChange
Caitong asset management-1.00
Gamma investing-2.00
True wealth design-9.00
Advisor group-10.00
Farther finance advisors-10.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202551-49.00%21,959,982-58.38%300.57%19-53.66%20-39.39%
Sep 30, 202595-13.64%52,043,0020.86%721.41%41-24.07%28-31.71%
Jun 30, 2025115-12.21%55,620,77331.52%772.22%58-1.69%42-14.29%
Mar 31, 2025134-8.22%58,450,755-9.27%810.99%60-34.07%4963.33%
Dec 31, 20241390.72%61,824,330-12.88%860.87%8519.72%28-26.32%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Eventide Healthcare & Life Sciences I2.83M3.96%-2.12M
Vanguard US Total Market Shares ETF1.89M2.64%-
Vanguard Total Stock Mkt Idx Inv1.69M2.62%154.15K
Eventide Gilead N1.64M2.30%-1.94M
Fidelity Growth Compy Commingled Pl O1.16M1.63%-
FIAM Small Cap Core CIT Cl B886.80K1.25%11.50K
Fidelity Growth Compy Commingled Pl S881.46K1.24%-280.77K
FIAM Small Cap Core Composite866.20K1.22%289.81K
PRIMECAP Odyssey Aggressive Growth676.40K1.04%-
Fidelity Small Cap Growth734.93K1.03%-

Recent Insider Transactions

DateNameRoleActivityValue
Feb 09, 2026Bruns Ingmar Chief Medical OfficerSell$801.62
Feb 06, 2026Bruns Ingmar Chief Medical OfficerSell$7.20K
Feb 09, 2026Vultaggio Vincent PAO and PFOSell$8.09K
Feb 06, 2026Vultaggio Vincent PAO and PFOSell$72.77K
Feb 10, 2026Vultaggio Vincent PAO and PFOSell$16.70K

Insider Transactions Trends

DateBuySell
2026 Q1-9
2025 Q411
2025 Q3--
2025 Q21-
2025 Q144

ZNTL Ownership FAQ

Who Owns Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals shareholders are primarily institutional investors at 30.44%, followed by 22.46% insiders and 47.10% retail investors. The average institutional ownership in Zentalis Pharmaceuticals's industry, Biotech Stocks , is 381.47%, which Zentalis Pharmaceuticals falls below.

Who owns the most shares of Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals’s largest shareholders are Blackrock (4.82M shares, 6.80%), Renaissance (2.88M shares, 4.00%), and Vanguard group (2.86M shares, 3.96%). Together, they hold 14.75% of Zentalis Pharmaceuticals’s total shares outstanding.

Does Blackrock own Zentalis Pharmaceuticals?

Yes, BlackRock owns 6.80% of Zentalis Pharmaceuticals, totaling 4.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 19.71M$. In the last quarter, BlackRock increased its holdings by 172.79K shares, a 3.72% change.

Who is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Mayo clinic is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 25.27% of its assets in 187.14K Zentalis Pharmaceuticals shares, valued at 765.42K$.

Who is the top mutual fund holder of Zentalis Pharmaceuticals shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Zentalis Pharmaceuticals shares, with 3.96% of its total shares outstanding invested in 2.83M Zentalis Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools